Oncology

Ripretinib appears safe, effective in KIT-altered metastatic melanoma

Ripretinib, a broad-spectrum KIT and platelet-derived growth factor receptor A switch-control tyrosine kinase inhibitor, was found to be safe and effective in patients with KIT-altered metastatic melanoma, according to trial results. In this study, 26 patients with KIT-altered metastatic melanoma were treated with 150 mg once daily ripretinib in 28-day...